Bioxytran, Inc. entered into a commercial Distribution Agreement on February 10, 2026, with Khoury Medical LTD to commercialize A-SUQAR®, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG) formulation, in permitted markets. The agreement grants distribution rights initially non-exclusive, with potential volume-based exclusivity upon reaching purchase thresholds.
Key takeaways
Entered Distribution Agreement with Khoury Medical LTD on February 10, 2026
Khoury Medical to commercialize A-SUQAR® chewable tablets (2,000 mg Compound per tablet, 1,760 mg PHGG) in permitted markets
Distribution right limited to pharmacy channels, initially non-exclusive
Exclusivity triggered upon purchases of [***] Units in 2026 or later years, followed by 6-month exclusive period after initial [***] Units
Bioxytran retains all product liability and IP ownership
Issued press release on February 17, 2026 announcing the agreement